Genetic and epigenetic signatures in human hepatocellular carcinoma: A systematic review

Current Genomics

Volumn 12, Issue 2, 2011, Pages 130-137

  Nishida, Naoshi ^a   Goe, Ajay ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DNA methylation; Hepatocellular carcinoma; Mutation; Oncogene; Oncogenic pathway; Tumor suppressor gene

Indexed keywords

MICRORNA; PROTEIN P53; RETINOBLASTOMA PROTEIN;

CANCER GENETICS; CELL ADHESION; CELL CYCLE REGULATION; CELL GROWTH; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; DNA METHYLATION; EPIGENETICS; GENE ACTIVATION; GENE DISRUPTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; HEPATITIS VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOLECULAR DIAGNOSIS; ONCOGENE; PHENOTYPE; POINT MUTATION; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; VIRUS INFECTION;

EID: 79955599940     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920211795564359     Document Type: Review

References (66)

1. Nishida, N.; Nishimura, T.; Ito, T.; Komeda, T.; Fukuda, Y.; Nakao, K. Chromosomal instability and human hepatocarcinogenesis. Histol. Histopathol., 2003, 18, 897-909.
2. Brown, C. J.; Lain, S.; Verma, C. S.; Fersht, A. R.; Lane, D. P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer, 2009, 9, 862-873.
3. Hussain, S. P.; Schwank, J.; Staib, F.; Wang, X. W.; Harris, C. C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene, 2007, 26, 2166-2176.
4. Nishida, N.; Fukuda, Y.; Kokuryu, H.; Toguchida, J.; Yandell, D. W.; Ikenega, M.; Imura, H.; Ishizaki, K. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res., 1993, 53, 368-372.
5. Aguilar, F.; Harris, C. C.; Sun, T.; Hollstein, M.; Cerutti, P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science, 1994, 264, 1317-1319.
6. Aguilar, F.; Hussain, S. P.; Cerutti, P. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA, 1993, 90, 8586-8590.
7. Kirk, G. D.; Camus-Randon, A. M.; Mendy, M.; Goedert, J. J.; Merle, P.; Trepo, C.; Brechot, C.; Hainaut, P.; Montesano, R. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J. Natl. Cancer Inst., 2000, 92, 148-153.
8. Hulla, J. E.; Chen, Z. Y.; Eaton, D. L. Aflatoxin B1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res., 1993, 53, 9-11.
9. Madden, C. R.; Finegold, M. J.; Slagle, B. L. Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J. Virol., 2002, 76, 11770-11774.
10. Wang, X. W.; Gibson, M. K.; Vermeulen, W.; Yeh, H.; Forrester, K.; Sturzbecher, H. W.; Hoeijmakers, J. H.; Harris, C. C. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 1995, 55, 6012-6016.
11. Ambs, S.; Bennett, W. P.; Merriam, W. G.; Ogunfusika, M. O.; Oser, S. M.; Harrington, A. M.; Shields, P. G.; Felley-Bosco, E.; Hussain, S. P.; Harris, C. C. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl. Cancer Inst., 1999, 91, 86-88.
12. Zhang, Y.; Xiong, Y.; Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 1998, 92, 725-734.
13. Tannapfel, A.; Busse, C.; Weinans, L.; Benicke, M.; Katalinic, A.; Geissler, F.; Hauss, J.; Wittekind, C. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene, 2001, 20, 7104-7109.
14. Ito, T.; Nishida, N.; Fukuda, Y.; Nishimura, T.; Komeda, T.; Nakao, K. Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas. J. Gastroenterol., 2004, 39, 355-361.
15. Kao J. T.; Chuah S. K.; Huang C. C.; Chen C. L.; Wang C. C.; Hung C. H.; Chen C. H.; Wang J. H.; Lu S. N.; Lee C. M.; Changchien C. S.; Hu T. H. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection. Liver Int., 2007, 27, 772-81.
16. Han, H. J.; Jung, E. Y.; Lee, W. J.; Jang, K. L. Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein. FEBS Lett., 2002, 518, 169-172.
17. Ito, Y.; Matsuura, N.; Sakon, M.; Miyoshi, E.; Noda, K.; Takeda, T.; Umeshita, K.; Nagano, H.; Nakamori, S.; Dono, K.; Tsujimoto, M.; Nakahara, M.; Nakao, K.; Taniguchi, N.; Monden, M. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology, 1999, 30, 90-99.
18. Lei, P. P.; Zhang, Z. J.; Shen, L. J.; Li, J. Y.; Zou, Q.; Zhang, H. X. Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J. Gastroenterol., 2005, 11, 4587-4591.
19. Lukas, J.; Parry, D.; Aagaard, L.; Mann, D. J.; Bartkova, J.; Strauss, M.; Peters, G.; Bartek, J. Retinoblastoma-proteindependent cell-cycle inhibition by the tumour suppressor p16. Nature, 1995, 375, 503-506.
20. Nishida, N.; Fukuda, Y.; Komeda, T.; Kita, R.; Sando, T.; Furukawa, M.; Amenomori, M.; Shibagaki, I.; Nakao, K.; Ikenaga, M. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res., 1994, 54, 3107-3110.
21. Nishida, N.; Fukuda, Y.; Ishizaki, K.; Nakao, K. Alteration of cell cycle-related genes in hepatocarcinogenesis. Histol. Histopathol., 1997, 12, 1019-1025.
22. Azechi, H.; Nishida, N.; Fukuda, Y.; Nishimura, T.; Minata, M.; Katsuma, H.; Kuno, M.; Ito, T.; Komeda, T.; Kita, R.; Takahashi, R.; Nakao, K. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology, 2001, 60, 346-354.
23. Nishida, N.; Fukuda, Y.; Kokuryu, H.; Sadamoto, T.; Isowa, G.; Honda, K.; Yamaoka, Y.; Ikenaga, M.; Imura, H.; Ishizaki, K. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int. J. Cancer, 1992, 51, 862-868.
24. Zhang, X.; Xu, H. J.; Murakami, Y.; Sachse, R.; Yashima, K.; Hirohashi, S.; Hu, S. X.; Benedict, W. F.; Sekiya, T. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res., 1994, 54, 4177-4182.
25. Roncalli, M.; Bianchi, P.; Bruni, B.; Laghi, L.; Destro, A.; Di Gioia, S.; Gennari, L.; Tommasini, M.; Malesci, A.; Coggi, G. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology, 2002, 36, 427-432.
26. Kita, R.; Nishida, N.; Fukuda, Y.; Azechi, H.; Matsuoka, Y.; Komeda, T.; Sando, T.; Nakao, K.; Ishizaki, K. Infrequent alterations of the p16INK4A gene in liver cancer. Int. J. Cancer, 1996, 67, 176-180.
27. Matsuda, Y.; Ichida, T.; Matsuzawa, J.; Sugimura, K.; Asakura, H. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology, 1999, 116, 394-400.
28. Nishida, N.; Nishimura, T.; Nagasaka, T.; Ikai, I.; Goel, A.; Boland, C. R. Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res., 2007, 67, 4586-4594.
29. Li, X.; Hui, A. M.; Sun, L.; Hasegawa, K.; Torzilli, G.; Minagawa, M.; Takayama, T.; Makuuchi, M. p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin. Cancer Res., 2004, 10, 7484-7489.
30. Rubinfeld, B.; Albert, I.; Porfiri, E.; Fiol, C.; Munemitsu, S.; Polakis, P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science, 1996, 272, 1023-1026.
31. Matsumine, A.; Ogai, A.; Senda, T.; Okumura, N.; Satoh, K.; Baeg, G. H.; Kawahara, T.; Kobayashi, S.; Okada, M.; Toyoshima, K.; Akiyama, T. Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science, 1996, 272, 1020-1023.
32. Boutros, M.; Mihaly, J.; Bouwmeester, T.; Mlodzik, M. Signaling specificity by Frizzled receptors in Drosophila. Science, 2000, 288, 1825-1828.
33. Nishisho, I.; Nakamura, Y.; Miyoshi, Y.; Miki, Y.; Ando, H.; Horii, A.; Koyama, K.; Utsunomiya, J.; Baba, S.; Hedge, P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science, 1991, 253, 665-669.
34. Renkonen, E. T.; Nieminen, P.; Abdel-Rahman, W. M.; Moisio, A. L.; Jarvela, I.; Arte, S.; Jarvinen, H. J.; Peltomaki, P. Adenomatous polyposis families that screen APC mutation-negative by conventional methods are genetically heterogeneous. J. Clin. Oncol., 2005, 23, 5651-5659.
35. Guilford, P.; Hopkins, J.; Harraway, J.; McLeod, M.; McLeod, N.; Harawira, P.; Taite, H.; Scoular, R.; Miller, A.; Reeve, A. E. Ecadherin germline mutations in familial gastric cancer. Nature, 1998, 392, 402-405.
36. Morin, P. J.; Sparks, A. B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K. W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science, 1997, 275, 1787-1790.
37. Gamallo, C.; Palacios, J.; Moreno, G.; Calvo de Mora, J.; Suarez, A.; Armas, A. beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am. J. Pathol., 1999, 155, 527-536.
38. Taniguchi, K.; Roberts, L. R.; Aderca, I. N.; Dong, X.; Qian, C.; Murphy, L. M.; Nagorney, D. M.; Burgart, L. J.; Roche, P. C.; Smith, D. I.; Ross, J. A.; Liu, W. Mutational spectrum of betacatenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene, 2002, 21, 4863-4871.
39. Zucman-Rossi, J.; Benhamouche, S.; Godard, C.; Boyault, S.; Grimber, G.; Balabaud, C.; Cunha, A. S.; Bioulac-Sage, P.; Perret, C. Differential effects of inactivated Axin1 and activated betacatenin mutations in human hepatocellular carcinomas. Oncogene, 2007, 26, 774-780.
40. Katoh, H.; Shibata, T.; Kokubu, A.; Ojima, H.; Kosuge, T.; Kanai, Y.; Hirohashi, S. Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: a case report. Genes Chromosomes Cancer, 2006, 45, 1050-1057.
41. Fujii, K.; Furukawa, F.; Matsuyoshi, N. Ligand activation of overexpressed epidermal growth factor receptor results in colony dissociation and disturbed E-cadherin function in HSC-1 human cutaneous squamous carcinoma cells. Exp. Cell Res., 1996, 223, 50-62.
42. Garcia, S.; Martini, F.; De Micco, C.; Andrac, L.; Hardwigsen, J.; Sappa, P.; Lavaut, M. N.; Le Treut, Y. P.; Charpin, C. Immunoexpression of E-cadherin and beta-catenin correlates to survival of patients with hepatocellular carcinomas. Int. J. Oncol., 1998, 12, 443-447.
43. Lim, S. O.; Gu, J. M.; Kim, M. S.; Kim, H. S.; Park, Y. N.; Park, C. K.; Cho, J. W.; Park, Y. M.; Jung, G. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology, 2008, 135, 2128-2140.
44. Kondo, Y.; Kanai, Y.; Sakamoto, M.; Mizokami, M.; Ueda, R.; Hirohashi, S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis--A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology, 2000, 32, 970-979.
45. Park, I. Y.; Sohn, B. H.; Yu, E.; Suh, D. J.; Chung, Y. H.; Lee, J. H.; Surzycki, S. J.; Lee, Y. I. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology, 2007, 132, 1476-1494.
46. Jung, J. K.; Arora, P.; Pagano, J. S.; Jang, K. L. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res., 2007, 67, 5771-5778.
47. Arora, P.; Kim, E. O.; Jung, J. K.; Jang, K. L. Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett., 2008, 261, 244-252.
48. Nishida, N.; Nagasaka, T.; Nishimura, T.; Ikai, I.; Boland, C. R.; Goel, A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology, 2008, 47, 908-918.
49. Nishida, N. Impact of hepatitis virus and aging on DNA methylation in human hepatocarcinogenesis. Histol. Histopathol., 2010, 25, 647-654.
50. Wong, I. H.; Lo, Y. M.; Zhang, J.; Liew, C. T.; Ng, M. H.; Wong, N.; Lai, P. B.; Lau, W. Y.; Hjelm, N. M.; Johnson, P. J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res., 1999, 59, 71-73.
51. Wang, J.; Qin, Y.; Li, B.; Sun, Z.; Yang, B. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin. Biochem., 2006, 39, 344-348.
52. Zhang, Y. J.; Wu, H. C.; Shen, J.; Ahsan, H.; Tsai, W. Y.; Yang, H. I.; Wang, L. Y.; Chen, S. Y.; Chen, C. J.; Santella, R. M. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res., 2007, 13, 2378-2384.
53. Chiang, D. Y.; Villanueva, A.; Hoshida, Y.; Peix, J.; Newell, P.; Minguez, B.; LeBlanc, A. C.; Donovan, D. J.; Thung, S. N.; Sole, M.; Tovar, V.; Alsinet, C.; Ramos, A. H.; Barretina, J.; Roayaie, S.; Schwartz, M.; Waxman, S.; Bruix, J.; Mazzaferro, V.; Ligon, A. H.; Najfeld, V.; Friedman, S. L.; Sellers, W. R.; Meyerson, M.; Llovet, J. M. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res., 2008, 68, 6779-6788.
54. Kutay, H.; Bai, S.; Datta, J.; Motiwala, T.; Pogribny, I.; Frankel, W.; Jacob, S. T.; Ghoshal, K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell Biochem., 2006, 99, 671-678.
55. Gramantieri, L.; Ferracin, M.; Fornari, F.; Veronese, A.; Sabbioni, S.; Liu, C. G.; Calin, G. A.; Giovannini, C.; Ferrazzi, E.; Grazi, G. L.; Croce, C. M.; Bolondi, L.; Negrini, M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res., 2007, 67, 6092-6099.
56. Fornari, F.; Gramantieri, L.; Ferracin, M.; Veronese, A.; Sabbioni, S.; Calin, G. A.; Grazi, G. L.; Giovannini, C.; Croce, C. M.; Bolondi, L.; Negrini, M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27, 5651-5661.
57. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S. T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133, 647-658.
58. Ji, J.; Shi, J.; Budhu, A.; Yu, Z.; Forgues, M.; Roessler, S.; Ambs, S.; Chen, Y.; Meltzer, P. S.; Croce, C. M.; Qin, L. X.; Man, K.; Lo, C. M.; Lee, J.; Ng, I. O.; Fan, J.; Tang, Z. Y.; Sun, H. C.; Wang, X. W. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med., 2009, 361, 1437-1447.
59. Naugler, W. E.; Sakurai, T.; Kim, S.; Maeda, S.; Kim, K.; Elsharkawy, A. M.; Karin, M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 2007, 317, 121-124.
60. Nakagawa, H.; Maeda, S.; Yoshida, H.; Tateishi, R.; Masuzaki, R.; Ohki, T.; Hayakawa, Y.; Kinoshita, H.; Yamakado, M.; Kato, N.; Shiina, S.; Omata, M. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int. J. Cancer, 2009, 125, 2264-2269.
61. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H-W.; Chang, T-C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137, 1005-1017.
62. Budhu, A.; Jia, H. L.; Forgues, M.; Liu, C. G.; Goldstein, D.; Lam, A.; Zanetti, K. A.; Ye, Q. H.; Qin, L. X.; Croce, C. M.; Tang, Z. Y.; Wang, X. W. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology, 2008, 47, 897-907.
63. Varnholt, H.; Drebber, U.; Schulze, F.; Wedemeyer, I.; Schirmacher, P.; Dienes, H. P.; Odenthal, M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology, 2008, 47, 1223-1232.
64. Ura, S.; Honda, M.; Yamashita, T.; Ueda, T.; Takatori, H.; Nishino, R.; Sunakozaka, H.; Sakai, Y.; Horimoto, K.; Kaneko, S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology, 2009, 49, 1098-1112.
65. Xiong, Y.; Fang, J. H.; Yun, J. P.; Yang, J.; Zhang, Y.; Jia, W. H.; Zhuang, S. M. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology, 2010, 51, 836-845.
66. Yao, J.; Liang, L.; Huang, S.; Ding, J.; Tan, N.; Zhao, Y.; Yan, M.; Ge, C.; Zhang, Z.; Chen, T.; Wan, D.; Yao, M.; Li, J.; Gu, J.; He, X. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology, 2010, 51, 846-856.